Table 3 HER2 classification changes in the NAT and no-NAT group from paired biopsy and surgical specimens
From: Effect of neoadjuvant therapy on breast cancer biomarker profile
Surgery Biopsy | Negative | Ambiguous | Positive | p value | No. cases with loss of HER2 | No. cases with gain of HER2 | |
|---|---|---|---|---|---|---|---|
No-NAT group (N = 61) | Negative | 40 | 5 | 2 | 0.4165 | 2 | 8 |
Ambiguous | 1 | 3 | 1 | ||||
Positive | 0 | 1 | 8 | ||||
NAT group (N = 78) | Negative | 55 | 4 | 1 | 0.6616 | 4 | 5 |
Ambiguous | 2 | 5 | 0 | ||||
Positive | 2 | 0 | 8 | ||||
Unkown | 0 | 1 | 0 |